2018
DOI: 10.17116/oftalma2018134212-22
|View full text |Cite
|
Sign up to set email alerts
|

Anti-VEGF therapy for diabetic macular edema. From theory to clinical practice

Abstract: Aflibercept can be used as first-choice drug for treatment of DME patients (both therapy-naïve and unresponsive to previous ranibizumab therapy) to improve anatomical parameters and visual function.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 25 publications
0
0
0
Order By: Relevance
“…Шундай қилиб, даволашнинг ушбу услуби интравитреал қўлланадиган, ДМШ ни даволашда самарадорлиги кўпроқ бўлган терапия, анти-VEGF га (VEGF -vascular endothelial growth factor-ўсишнинг томир эндотелиал омили) ўз ўрнини бўшатиб берди [3,17,18,19].…”
Section: передовая офтальмологияunclassified
“…Шундай қилиб, даволашнинг ушбу услуби интравитреал қўлланадиган, ДМШ ни даволашда самарадорлиги кўпроқ бўлган терапия, анти-VEGF га (VEGF -vascular endothelial growth factor-ўсишнинг томир эндотелиал омили) ўз ўрнини бўшатиб берди [3,17,18,19].…”
Section: передовая офтальмологияunclassified